NCT02448264View on ClinicalTrials.gov

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Hereditary Angioedema
Interventions
DRUG

BCX7353

DRUG

Placebo to match BCX7353

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY